AGTX on OTC
Agentix Corp.
American biological products company based in Dana Point, listed on OTC (AGTX)1
In its 2026 annual report the company says: “We are a clinical development stage corporation with a focus on pharmaceutical treatments in the metabolic disease space and have not yet generated or realized meaningful revenues from our business.”5
$0.02 up 0.00 (0.00%)Price as of Oct 15, 2026 at 14:59 UTC
Last updated Oct 21, 2026.
Overview
Compare with CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC., Allogene Therapeutics, Inc. or Senti Biosciences Holdings, Inc., or pick any stock.
- TickerAGTX on OTC1
- IndustryBiological Products, (No Diagnostic Substances)1
- HeadquartersDana Point, California1
- Incorporated inNV4
- Business address32932 Pacific Coast Highway, #14-254, Dana Point, Ca 926294
- Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company4
See how the biggest companies compare on our leaderboards
The Company was incorporated in the State of Nevada on April 18, 2013 and has established a fiscal year end of March 31. Effective June 17, 2019, we changed our name from FairWind Energy, Inc. to Agentix Corp. and to better reflect the new focus of our business. We are a clinical development stage corporation with a focus on pharmaceutical treatments in the metabolic disease space and have not yet generated or realized meaningful revenues from our business.5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2023
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.3
| Period ending | 2026-03-31 | 2025-03-31 |
|---|---|---|
| Professional fees | $252.0K | $262.4K |
| Research and development | $125.1K | $181.0K |
| General and administrative expenses | $68.1K | $69.9K |
| Total operating expenses | $445.2K | $513.3K |
| Loss from operations | -$445.2K | -$513.3K |
| Foreign exchange gain (loss) | -$24.6K | $11.1K |
| Interest expense, net | $80.1K | $42.7K |
| Interest income | $0 | $0 |
| Other income | -$15.1K | $0 |
| Other loss (income), net | $40.4K | $53.8K |
| Loss before income tax provision | -$485.6K | -$567.0K |
| Income tax provision | $0 | $0 |
| Net loss | -$485.6K | -$567.0K |
| Change in foreign currency translation, net of tax | $9.0K | -$23.0K |
| Total comprehensive loss | -$476.6K | -$602.2K |
| - Basic and diluted | -$0.01 | -$0.01 |
| - Basic and diluted | 40.1M shares | 40.1M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.3
| Period ending | 2026-03-31 | 2025-03-31 | 2024-03-31 |
|---|---|---|---|
| Cash | $771 | $4.5K | $6.5K |
| Prepaid expense and other current assets | $0 | $95.8K | |
| Total current assets | $771 | $100.3K | |
| Total assets | $771 | $100.3K | |
| Accounts payable | $715.9K | $968.9K | |
| Accounts payable - related parties | $2.4M | $1.9M | |
| Note payable - related party | $353.4K | $243.0K | |
| Accrued expenses | $143.9K | $60.2K | |
| Total current liabilities | $3.6M | $3.2M | |
| Long Term Liabilities | $0 | $0 | |
| Total liabilities | $3.6M | $3.2M | |
| Commitments and Contingencies | $0 | $0 | |
| Common stock par value $0.001: 50,000,000 shares authorized; 40,066,951 shares issued and outstanding as of March 31, 2026 and March 31, 2025, respectively | $40.1K | $40.1K | |
| Common stock to be issued (357,102 at March 31, 2026 and March 31, 2025, respectively) | $53.5K | $53.5K | |
| Additional paid-in capital | $3.3M | $3.3M | |
| Accumulated other comprehensive income | $29.8K | $35.4K | |
| Accumulated deficit | -$7.0M | -$6.5M | |
| Total stockholders' deficit | -$3.6M | -$3.1M | -$2.6M |
| Total liabilities and stockholders' deficit | $771 | $100.3K | |
| Common stock, shares par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 50.0M shares | 50.0M shares | |
| Common stock, shares issued | 40.1M shares | 40.1M shares | |
| Common stock, shares outstanding | 40.1M shares | 40.1M shares | |
| Common stock to be issued | 357.1K shares | 357.1K shares |
| Period ending | 2026-03-31 | 2025-03-31 | 2024-03-31 |
|---|---|---|---|
| Cash | $771 | $4.5K | $6.5K |
| Prepaid expense and other current assets | $0 | $95.8K | |
| Total current assets | $771 | $100.3K | |
| Total assets | $771 | $100.3K | |
| Accounts payable | $715.9K | $968.9K | |
| Accounts payable - related parties | $2.4M | $1.9M | |
| Note payable - related party | $353.4K | $243.0K | |
| Accrued expenses | $143.9K | $60.2K | |
| Total current liabilities | $3.6M | $3.2M | |
| Long Term Liabilities | $0 | $0 | |
| Total liabilities | $3.6M | $3.2M | |
| Commitments and Contingencies | $0 | $0 | |
| Common stock par value $0.001: 50,000,000 shares authorized; 40,066,951 shares issued and outstanding as of March 31, 2026 and March 31, 2025, respectively | $40.1K | $40.1K | |
| Common stock to be issued (357,102 at March 31, 2026 and March 31, 2025, respectively) | $53.5K | $53.5K | |
| Additional paid-in capital | $3.3M | $3.3M | |
| Accumulated other comprehensive income | $29.8K | $35.4K | |
| Accumulated deficit | -$7.0M | -$6.5M | |
| Total stockholders' deficit | -$3.6M | -$3.1M | -$2.6M |
| Total liabilities and stockholders' deficit | $771 | $100.3K | |
| Common stock, shares par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 50.0M shares | 50.0M shares | |
| Common stock, shares issued | 40.1M shares | 40.1M shares | |
| Common stock, shares outstanding | 40.1M shares | 40.1M shares | |
| Common stock to be issued | 357.1K shares | 357.1K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.3
| Period ending | 2026-03-31 | 2025-03-31 |
|---|---|---|
| Net loss | -$485.6K | -$567.0K |
| Gain on settlement of payables | -$20.6K | $0 |
| Prepayments and other current assets | $95.8K | $4.0K |
| Accrued expenses, accounts payable and accounts payable-related party | $301.9K | $437.9K |
| Net Cash Provided by (Used in) Operating Activities | -$108.5K | -$125.1K |
| Cash Flows from Investing Activities | $0 | $0 |
| Proceeds from issuance of debt | $110.5K | $100.0K |
| Net Cash Provided by Financing Activities | $110.5K | $100.0K |
| Effects of Foreign Exchange Rate Changes on Cash | -$5.6K | $23.0K |
| Net Change in Cash | -$3.7K | -$2.1K |
| Interest paid | $0 | $0 |
| Income tax paid | $0 | $0 |
No quarter-by-quarter statement was filed.
What it owns
What Agentix Corp. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Investments
Properties, in its own words
Our current business address is 32932 Pacific Coast Highway, #14-254, Dana Point, California 92629. We believe that this space is adequate for our current needs. Our telephone number is (321) 299-2014.
Item 2 of the 10-K filed Jul 1, 2026.5
Leadership
Who has led Agentix Corp., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
- Chief executive officerMichael Winterhalter Apr 7, 2015 to Apr 20, 201614
- PresidentScott B. Stevens Jun 11, 2019 to Nov 5, 201915
- PresidentMichael Winterhalter Apr 7, 2015 to Apr 20, 201614
- Chief financial officerMichael Winterhalter Apr 7, 2015 to Apr 20, 201614
Board members and other officers (7)
- Pres, Treasurer & SecretaryMichael Winterhalter May 21, 2020 to May 21, 202016
- Secretary and TreasurerRobert K. Whalen Jun 18, 2019 to Jun 18, 201917
- Board memberScott B. Stevens Jun 11, 2019 to Nov 5, 201915
- Board memberRobert K. Whalen Jun 18, 2019 to Jun 18, 201917
- Board memberEric Krogius Apr 6, 2015 to Apr 20, 201618
- Board memberMichael Winterhalter Apr 7, 2015 to May 21, 202014
- Board memberRobert Drust Apr 13, 2015 to Apr 20, 201619
Former names
- FairWind Energy Inc.Apr 1, 2014 to Jun 27, 20194
Timeline
Filings
34 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 2 major events, 11 other. The latest 20:
- Aug 10, 202610-Q EDGAR
- Jul 1, 202610-K EDGAR
- Feb 17, 202610-Q EDGAR
- Nov 20, 202510-Q EDGAR
- Aug 22, 202510-Q EDGAR
- Aug 15, 2025NT 10-Q EDGAR
- Jul 16, 202510-K EDGAR
- Jul 1, 2025NT 10-K EDGAR
- Feb 18, 202510-Q EDGAR
- Feb 14, 2025NT 10-Q EDGAR
- Nov 18, 202410-Q EDGAR
- Nov 14, 2024NT 10-Q EDGAR
- Sep 25, 202410-Q EDGAR
- Aug 30, 202410-K EDGAR
- Aug 15, 2024NT 10-Q EDGAR
- Jul 1, 2024NT 10-K EDGAR
- Feb 14, 202410-Q EDGAR
- Nov 20, 202310-Q EDGAR
- Nov 14, 2023NT 10-Q EDGAR
- Aug 22, 202310-Q EDGAR
The 34 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
SEC filer profile
How Agentix Corp. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARAgentix Corp.1
- CIK0001603345
- Employer ID (EIN)46-28762825
- Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company5
- Incorporated inNevada5
- Fiscal year endsMarch 311
- Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address32932 Pacific Coast Highway, #14-254, Dana Point, CA 926291
- Phone321-229-20141
- Shares outstanding40,066,951 as of Aug 7, 202612
- Public float$1.3M as of Sep 30, 20255
- AuditorFruci & Associates II, PLLC, Spokane, Washington PCAOB ID 5525; no auditor attestation of internal control over financial reporting5
- On EDGAR sinceApr 1, 20141
- Filings153 in all: 10-Q (36), 8-K (15), 4 (14), NT 10-Q (14), 10-K (11), 3 (9), NT 10-K (9), CORRESP (5)1
All 28 form types
S-1/A (5), UPLOAD (5), EFFECT (4), SC 13D (4), POS AM (3), 424B3 (2), D (2), S-1 (2), SC 13D/A (2), 10-K/A (1), 10-KT (1), 8-A12G (1), 8-K/A (1), DEF 14C (1), PRE 14C (1), RW (1), S-8 (1), S-8 POS (1), SC 13G (1), SC 13G/A (1)
- Latest filingsAnnual report (10-K) Jul 1, 2026
Quarterly report (10-Q) Aug 10, 2026
Latest 8-K (8-K) Jun 14, 2022
Risk factors and legal proceedings
Legal proceedings
We are not currently involved in any legal proceedings and we are not aware of any pending or potential legal actions.
The opening of Item 3, Legal Proceedings.5
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARAgentix Corp. filings on SEC EDGAR
- 2Yahoo FinanceAGTX quote
- 3SEC EDGARAgentix Corp. 10-K for fiscal 2026
- 4SEC EDGARAgentix Corp. filings on SEC EDGAR
- 5
- 6SEC EDGARAgentix Corp. 10-K for fiscal 2023
- 7SEC EDGARAgentix Corp. 10-K for fiscal 2021
- 8SEC EDGARAgentix Corp. 10-K for fiscal 2019
- 9SEC EDGARAgentix Corp. 10-K for fiscal 2023
- 10SEC EDGARAgentix Corp. 10-Q for fiscal 2025
- 11SEC EDGARAgentix Corp. 10-Q for fiscal 2025
- 12SEC EDGARAgentix Corp. 10-Q for fiscal 2026
- 13SEC EDGARAgentix Corp. 10-K for fiscal 2023
- 14
- 15SEC EDGARScott B. Stevens, President
- 16
- 17
- 18SEC EDGAREric Krogius, Board member
- 19SEC EDGARRobert Drust, Board member
- 20SEC EDGARExecutive or director change
- 21SEC EDGARRegulation FD disclosure